StreetInsider.com News Articles

Kura Oncology reports clinical trial data for cancer drug darlifarnib

Wed, 03 Jun 2026 06:55:41 -0400

Kura Oncology Inc. (NASDAQ: KURA) reported preliminary clinical trial data for its cancer drug candidate darlifarnib in combination with adagrasib for treating KRAS-mutant cancers, according to a company statement.

The Phase 1a trial data showed confirmed objective response rates of 67% in pancreatic cancer patients, 50% in non-small cell lung cancer patients, and 29% in KRAS inhibitor-naïve colorectal cancer patients. The study included 26 response-evaluable patients with KRAS G12C-mutated cancers who had received previous treatments.

Tumor shrinkage was observed in 77% of all patients and 94% of patients who had not previously received KRAS inhibitor treatment. Clinical activity was also noted in

Kura Oncology reports clinical trial data for cancer drug darlifarnib

Wed, 03 Jun 2026 06:55:41 -0400

Tumor shrinkage was observed in 77% of all patients and 94% of patients who had not previously received KRAS inhibitor treatment. Clinical activity was also noted in

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

Wed, 03 Jun 2026 06:53:00 -0400

– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients –

– Clinical activity observed in both KRAS inhibitor-naïve and KRAS inhibitor-pretreated patients –

– Preclinical data support broad applicability across the evolving RAS inhibitor landscape, including mutant-selective, pan-KRAS and RAS(ON) multi-selective inhibitors –

– New platform study designed to accelerate evaluation of darlifarnib across multiple targeted therapies, combinations, and disease settings –

– First planned platform combination,

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

Wed, 03 Jun 2026 06:53:00 -0400

– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients –

– Clinical activity observed in both KRAS inhibitor-naïve and KRAS inhibitor-pretreated patients –

– Preclinical data support broad applicability across the evolving RAS inhibitor landscape, including mutant-selective, pan-KRAS and RAS(ON) multi-selective inhibitors –

– New platform study designed to accelerate evaluation of darlifarnib across multiple targeted therapies, combinations, and disease settings –

– First planned platform combination,

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

Wed, 03 Jun 2026 06:53:00 -0400

– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients –

– Clinical activity observed in both KRAS inhibitor-naïve and KRAS inhibitor-pretreated patients –

– Preclinical data support broad applicability across the evolving RAS inhibitor landscape, including mutant-selective, pan-KRAS and RAS(ON) multi-selective inhibitors –

– New platform study designed to accelerate evaluation of darlifarnib across multiple targeted therapies, combinations, and disease settings –

– First planned platform combination,

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

Wed, 03 Jun 2026 06:53:00 -0400

– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients –

– Clinical activity observed in both KRAS inhibitor-naïve and KRAS inhibitor-pretreated patients –

– Preclinical data support broad applicability across the evolving RAS inhibitor landscape, including mutant-selective, pan-KRAS and RAS(ON) multi-selective inhibitors –

– New platform study designed to accelerate evaluation of darlifarnib across multiple targeted therapies, combinations, and disease settings –

– First planned platform combination,

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

Wed, 03 Jun 2026 06:53:00 -0400

– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients –

– Clinical activity observed in both KRAS inhibitor-naïve and KRAS inhibitor-pretreated patients –

– Preclinical data support broad applicability across the evolving RAS inhibitor landscape, including mutant-selective, pan-KRAS and RAS(ON) multi-selective inhibitors –

– New platform study designed to accelerate evaluation of darlifarnib across multiple targeted therapies, combinations, and disease settings –

– First planned platform combination,

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

Wed, 03 Jun 2026 06:53:00 -0400

– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients –

– Clinical activity observed in both KRAS inhibitor-naïve and KRAS inhibitor-pretreated patients –

– Preclinical data support broad applicability across the evolving RAS inhibitor landscape, including mutant-selective, pan-KRAS and RAS(ON) multi-selective inhibitors –

– New platform study designed to accelerate evaluation of darlifarnib across multiple targeted therapies, combinations, and disease settings –

– First planned platform combination,

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

Wed, 03 Jun 2026 06:53:00 -0400

– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients –

– Clinical activity observed in both KRAS inhibitor-naïve and KRAS inhibitor-pretreated patients –

– Preclinical data support broad applicability across the evolving RAS inhibitor landscape, including mutant-selective, pan-KRAS and RAS(ON) multi-selective inhibitors –

– New platform study designed to accelerate evaluation of darlifarnib across multiple targeted therapies, combinations, and disease settings –

– First planned platform combination,

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

Wed, 03 Jun 2026 06:53:00 -0400

– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients –

– Clinical activity observed in both KRAS inhibitor-naïve and KRAS inhibitor-pretreated patients –

– Preclinical data support broad applicability across the evolving RAS inhibitor landscape, including mutant-selective, pan-KRAS and RAS(ON) multi-selective inhibitors –

– New platform study designed to accelerate evaluation of darlifarnib across multiple targeted therapies, combinations, and disease settings –

– First planned platform combination,

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

Wed, 03 Jun 2026 06:53:00 -0400

– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients –

– Clinical activity observed in both KRAS inhibitor-naïve and KRAS inhibitor-pretreated patients –

– Preclinical data support broad applicability across the evolving RAS inhibitor landscape, including mutant-selective, pan-KRAS and RAS(ON) multi-selective inhibitors –

– New platform study designed to accelerate evaluation of darlifarnib across multiple targeted therapies, combinations, and disease settings –

– First planned platform combination,

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

Wed, 03 Jun 2026 06:53:00 -0400

– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients –

– Clinical activity observed in both KRAS inhibitor-naïve and KRAS inhibitor-pretreated patients –

– Preclinical data support broad applicability across the evolving RAS inhibitor landscape, including mutant-selective, pan-KRAS and RAS(ON) multi-selective inhibitors –

– New platform study designed to accelerate evaluation of darlifarnib across multiple targeted therapies, combinations, and disease settings –

– First planned platform combination,

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

Wed, 03 Jun 2026 06:53:00 -0400

– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients –

– Clinical activity observed in both KRAS inhibitor-naïve and KRAS inhibitor-pretreated patients –

– Preclinical data support broad applicability across the evolving RAS inhibitor landscape, including mutant-selective, pan-KRAS and RAS(ON) multi-selective inhibitors –

– New platform study designed to accelerate evaluation of darlifarnib across multiple targeted therapies, combinations, and disease settings –

– First planned platform combination,

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

Wed, 03 Jun 2026 06:53:00 -0400

– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients –

– Clinical activity observed in both KRAS inhibitor-naïve and KRAS inhibitor-pretreated patients –

– Preclinical data support broad applicability across the evolving RAS inhibitor landscape, including mutant-selective, pan-KRAS and RAS(ON) multi-selective inhibitors –

– New platform study designed to accelerate evaluation of darlifarnib across multiple targeted therapies, combinations, and disease settings –

– First planned platform combination,

Kura Oncology publishes ziftomenib combination study in Blood journal

Tue, 02 Jun 2026 08:33:35 -0400

Kura Oncology Inc (NASDAQ: KURA) and Kyowa Kirin Co Ltd announced publication of updated results from their KOMET-007 trial evaluating ziftomenib combined with venetoclax and azacitidine in patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.
The study included 64 response-evaluable patients who had received one to eight prior lines of therapy. Among venetoclax-naive patients receiving 600 mg ziftomenib daily, the composite complete remission rate reached 70% with 87% overall response rate. The median duration of composite complete remission was 9.2 months, and median overall survival was not reached after median follow-up of 10.7 months.
In venetoclax-experienced patients at the same dose, composite complete

Kura Oncology publishes ziftomenib combination study in Blood journal

Tue, 02 Jun 2026 08:33:35 -0400

Kura Oncology Inc (NASDAQ: KURA) and Kyowa Kirin Co Ltd announced publication of updated results from their KOMET-007 trial evaluating ziftomenib combined with venetoclax and azacitidine in patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.
The study included 64 response-evaluable patients who had received one to eight prior lines of therapy. Among venetoclax-naive patients receiving 600 mg ziftomenib daily, the composite complete remission rate reached 70% with 87% overall response rate. The median duration of composite complete remission was 9.2 months, and median overall survival was not reached after median follow-up of 10.7 months.
In venetoclax-experienced patients at the same dose, composite complete

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

Tue, 02 Jun 2026 08:32:00 -0400

– 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose –

– Central MRD negativity in 75% of CRc responders with no prior venetoclax exposure; median CRc duration was 9.2 months –

– Median OS not reached after median follow up of 10.7 months in patients with no prior venetoclax exposure –

– Combination was well tolerated, with low rates of differentiation syndrome and QTc prolongation observed –

SAN DIEGO and TOKYO, June 02, 2026 (GLOBE

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

Tue, 02 Jun 2026 08:32:00 -0400

– 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose –

– Central MRD negativity in 75% of CRc responders with no prior venetoclax exposure; median CRc duration was 9.2 months –

– Median OS not reached after median follow up of 10.7 months in patients with no prior venetoclax exposure –

– Combination was well tolerated, with low rates of differentiation syndrome and QTc prolongation observed –

SAN DIEGO and TOKYO, June 02, 2026 (GLOBE

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

Tue, 02 Jun 2026 08:32:00 -0400

– 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose –

– Central MRD negativity in 75% of CRc responders with no prior venetoclax exposure; median CRc duration was 9.2 months –

– Median OS not reached after median follow up of 10.7 months in patients with no prior venetoclax exposure –

– Combination was well tolerated, with low rates of differentiation syndrome and QTc prolongation observed –

SAN DIEGO and TOKYO, June 02, 2026 (GLOBE

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

Tue, 02 Jun 2026 08:32:00 -0400

– 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose –

– Central MRD negativity in 75% of CRc responders with no prior venetoclax exposure; median CRc duration was 9.2 months –

– Median OS not reached after median follow up of 10.7 months in patients with no prior venetoclax exposure –

– Combination was well tolerated, with low rates of differentiation syndrome and QTc prolongation observed –

SAN DIEGO and TOKYO, June 02, 2026 (GLOBE

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

Tue, 02 Jun 2026 08:32:00 -0400

– 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose –

– Central MRD negativity in 75% of CRc responders with no prior venetoclax exposure; median CRc duration was 9.2 months –

– Median OS not reached after median follow up of 10.7 months in patients with no prior venetoclax exposure –

– Combination was well tolerated, with low rates of differentiation syndrome and QTc prolongation observed –

SAN DIEGO and TOKYO, June 02, 2026 (GLOBE

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

Tue, 02 Jun 2026 08:32:00 -0400

– 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose –

– Central MRD negativity in 75% of CRc responders with no prior venetoclax exposure; median CRc duration was 9.2 months –

– Median OS not reached after median follow up of 10.7 months in patients with no prior venetoclax exposure –

– Combination was well tolerated, with low rates of differentiation syndrome and QTc prolongation observed –

SAN DIEGO and TOKYO, June 02, 2026 (GLOBE

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

Tue, 02 Jun 2026 08:32:00 -0400

– 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose –

– Central MRD negativity in 75% of CRc responders with no prior venetoclax exposure; median CRc duration was 9.2 months –

– Median OS not reached after median follow up of 10.7 months in patients with no prior venetoclax exposure –

– Combination was well tolerated, with low rates of differentiation syndrome and QTc prolongation observed –

SAN DIEGO and TOKYO, June 02, 2026 (GLOBE

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

Tue, 02 Jun 2026 08:32:00 -0400

– 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose –

– Central MRD negativity in 75% of CRc responders with no prior venetoclax exposure; median CRc duration was 9.2 months –

– Median OS not reached after median follow up of 10.7 months in patients with no prior venetoclax exposure –

– Combination was well tolerated, with low rates of differentiation syndrome and QTc prolongation observed –

SAN DIEGO and TOKYO, June 02, 2026 (GLOBE

Kura Oncology (KURA) Reiterated at Market Outperform by Citizens on FIT-001 Data Preview

Thu, 28 May 2026 05:21:27 -0400

Citizens analyst Reni J. Benjamin reiterated a Market Outperform rating and $24.00 price target on Kura Oncology (NASDAQ: KURA).
The analyst commented, "We reiterate our Market Outperform rating on Kura Oncology and price target of $24, based on a blended discounted EPS and revenue multiple analysis. Recently, Kura provided a preview of data from the darli + adagrasib arm of the FIT-001 study to be presented at ASCO, showcasing that the farnesyltransferase inhibitor (FTI) can combine well with Kras inhibitors. Building on prior clinical validation in cabo-(re)treated RCC, we view this dataset as an important step in establishing the FTI platform